Comparison of Topical Nepafenac 0.1 % and Prednisolone Acetate 1% as an Anti-Inflammatory after Vitrectomy in Rhegmatogenous Retinal Detachment

Minimizing Proliferative Vitreoretinopathy Reaction in Rhegmatogenous Retinal Detachment: Is There a Role of Preoperative Anti-Inflammatory?

“…The progression of PVR involves intricate mechanisms influenced by inflammatory processes or mediators, angiogenesis, and fibrotic changes, contributing to the formation of new blood vessels and the deposition of connective tissue. 2,3,4,5,6 The inflammatory response associated with PVR is characterized by elevated levels of arachidonic acid metabolites (PGE2 and COX-2), TGF-ß, and monocytes or macrophages in the vitreous. Djatikusumo et al study scrutinized the preoperative administration of nepafenac 0.1%, a non-steroidal anti-inflammatory drug, aimed at averting the emergence of PVR in patients diagnosed with RRD, thereby enhancing the anatomical success of postoperative vitrectomy.…”

“…Djatikusumo et al study scrutinized the preoperative administration of nepafenac 0.1%, a non-steroidal anti-inflammatory drug, aimed at averting the emergence of PVR in patients diagnosed with RRD, thereby enhancing the anatomical success of postoperative vitrectomy. 6,7,8 The research constituted a randomized clinical trial involving 61 subjects, partitioned into two distinct groups: 31 participants in the nepafenac 0.1% group and 30 in the control arm. Inclusion criteria entailed patients diagnosed with RRD concomitant with PVR grade A or B, scheduled for pars plana vitrectomy (PPV) interventions.…”